Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Enters At-Market Agreement to Sell up to $10.7M in Stock

NEW YORK – OpGen said last week that it has entered into an at-the-market sales agreement to sell up to $10.7 million worth of shares through H.C. Wainwright as the sales agent. 

In a filing with the US Securities and Exchange Commission, the firm said the deal allows OpGen to offer and sell up to an aggregate of $10.7 million worth of shares of its common stock at $.01 par value per share. Wainwright will sell the placement shares according to instructions from the company and will receive a commission of 3 percent of the gross sales proceeds. 

OpGen said the aggregate market value of its outstanding common stock was approximately $32.0 million, calculated based on 46,623,618 shares of common stock outstanding as of June 23 and a price per share of $.69. The firm has ended a previous at-the-market agreement with Wainwright and BTIG from 2020 for up to $22.1 million in proceeds.

In a prospectus, also filed with the SEC, the firm said it intends to use the proceeds from the offering to continue commercialization of its Acuitas AMR Gene Panel test, commercialize other products with a focus on the Unyvero platform, and support further development and commercialization of the Ares Genetics database. It will also support directed sales and marketing efforts, invest in manufacturing and operations infrastructure, and repay outstanding debts. The remaining proceeds will be used for working capital and other general corporate purposes.

OpGen also noted in the prospectus that on Feb. 28, it was notified by the Nasdaq that it no longer met the requirement to maintain a minimum closing bid price of $1.00 per share. It has until Aug. 29 to regain compliance but said it does not believe it will do so without a reverse stock split. 

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.